{"id":108,"date":"2014-09-26T10:54:27","date_gmt":"2014-09-26T08:54:27","guid":{"rendered":"https:\/\/melemapharma.de\/?page_id=108"},"modified":"2020-04-22T12:28:14","modified_gmt":"2020-04-22T10:28:14","slug":"willkommen-bei-melema-pharma","status":"publish","type":"page","link":"http:\/\/melemapharma.de\/en\/willkommen-bei-melema-pharma\/","title":{"rendered":"Welcome to MELEMA Pharma"},"content":{"rendered":"<p>MELEMA Pharma GmbH, a private biopharmaceutical company, is focusing on the development of immunotherapeutics having the potential to activate the patient\u2019s own immune system. A substantial medical challenge for the company is the immuno-oncology. The compounds under development are mainly based on natural compounds optimised by modern Gene Technological Procedures.<\/p>\n<p>Lead product is the immunepotentiator Aviscumine (ME-503), a therapeutic protein which recently completed a Phase II study in patients with refractory metastatic melanoma (stage IV) and for which the further clinical development is in preparation.<\/p>\n<p>MELEMA Pharma\u2019s strategy is to develop its drug candidates to Proof of Concept, and then bring in partners from academia and industry for the final stages of product development and commercialization.<\/p>","protected":false},"excerpt":{"rendered":"<p>MELEMA Pharma GmbH, a private biopharmaceutical company, is focusing on the development of immunotherapeutics having the potential to activate the patient\u2019s own immune system. A substantial medical challenge for the company is the immuno-oncology. The compounds under development are mainly based on natural compounds optimised by modern Gene Technological Procedures. Lead product is the immunepotentiator Aviscumine (ME-503), a therapeutic protein which recently completed a Phase II study in patients with refractory metastatic melanoma (stage IV) and for which the further clinical development is in preparation. MELEMA Pharma\u2019s strategy is to develop its drug candidates to Proof of Concept, and then bring in partners from academia and industry for the final stages of product development and commercialization.<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-108","page","type-page","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Welcome to MELEMA Pharma - MELEMA Pharma GmbH<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/melemapharma.de\/en\/willkommen-bei-melema-pharma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Welcome to MELEMA Pharma - MELEMA Pharma GmbH\" \/>\n<meta property=\"og:description\" content=\"MELEMA Pharma GmbH, a private biopharmaceutical company, is focusing on the development of immunotherapeutics having the potential to activate the patient\u2019s own immune system. A substantial medical challenge for the company is the immuno-oncology. The compounds under development are mainly based on natural compounds optimised by modern Gene Technological Procedures. Lead product is the immunepotentiator Aviscumine (ME-503), a therapeutic protein which recently completed a Phase II study in patients with refractory metastatic melanoma (stage IV) and for which the further clinical development is in preparation. MELEMA Pharma\u2019s strategy is to develop its drug candidates to Proof of Concept, and then bring in partners from academia and industry for the final stages of product development and commercialization.\" \/>\n<meta property=\"og:url\" content=\"http:\/\/melemapharma.de\/en\/willkommen-bei-melema-pharma\/\" \/>\n<meta property=\"og:site_name\" content=\"MELEMA Pharma GmbH\" \/>\n<meta property=\"article:modified_time\" content=\"2020-04-22T10:28:14+00:00\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\\\/\\\/melemapharma.de\\\/en\\\/willkommen-bei-melema-pharma\\\/\",\"url\":\"http:\\\/\\\/melemapharma.de\\\/en\\\/willkommen-bei-melema-pharma\\\/\",\"name\":\"Welcome to MELEMA Pharma - MELEMA Pharma GmbH\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/melemapharma.de\\\/#website\"},\"datePublished\":\"2014-09-26T08:54:27+00:00\",\"dateModified\":\"2020-04-22T10:28:14+00:00\",\"breadcrumb\":{\"@id\":\"http:\\\/\\\/melemapharma.de\\\/en\\\/willkommen-bei-melema-pharma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\\\/\\\/melemapharma.de\\\/en\\\/willkommen-bei-melema-pharma\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\\\/\\\/melemapharma.de\\\/en\\\/willkommen-bei-melema-pharma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/melemapharma.de\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Welcome to MELEMA Pharma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/melemapharma.de\\\/#website\",\"url\":\"https:\\\/\\\/melemapharma.de\\\/\",\"name\":\"MELEMA Pharma GmbH\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/melemapharma.de\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Welcome to MELEMA Pharma - MELEMA Pharma GmbH","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/melemapharma.de\/en\/willkommen-bei-melema-pharma\/","og_locale":"en_US","og_type":"article","og_title":"Welcome to MELEMA Pharma - MELEMA Pharma GmbH","og_description":"MELEMA Pharma GmbH, a private biopharmaceutical company, is focusing on the development of immunotherapeutics having the potential to activate the patient\u2019s own immune system. A substantial medical challenge for the company is the immuno-oncology. The compounds under development are mainly based on natural compounds optimised by modern Gene Technological Procedures. Lead product is the immunepotentiator Aviscumine (ME-503), a therapeutic protein which recently completed a Phase II study in patients with refractory metastatic melanoma (stage IV) and for which the further clinical development is in preparation. MELEMA Pharma\u2019s strategy is to develop its drug candidates to Proof of Concept, and then bring in partners from academia and industry for the final stages of product development and commercialization.","og_url":"http:\/\/melemapharma.de\/en\/willkommen-bei-melema-pharma\/","og_site_name":"MELEMA Pharma GmbH","article_modified_time":"2020-04-22T10:28:14+00:00","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/melemapharma.de\/en\/willkommen-bei-melema-pharma\/","url":"http:\/\/melemapharma.de\/en\/willkommen-bei-melema-pharma\/","name":"Welcome to MELEMA Pharma - MELEMA Pharma GmbH","isPartOf":{"@id":"https:\/\/melemapharma.de\/#website"},"datePublished":"2014-09-26T08:54:27+00:00","dateModified":"2020-04-22T10:28:14+00:00","breadcrumb":{"@id":"http:\/\/melemapharma.de\/en\/willkommen-bei-melema-pharma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/melemapharma.de\/en\/willkommen-bei-melema-pharma\/"]}]},{"@type":"BreadcrumbList","@id":"http:\/\/melemapharma.de\/en\/willkommen-bei-melema-pharma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/melemapharma.de\/"},{"@type":"ListItem","position":2,"name":"Welcome to MELEMA Pharma"}]},{"@type":"WebSite","@id":"https:\/\/melemapharma.de\/#website","url":"https:\/\/melemapharma.de\/","name":"MELEMA Pharma GmbH","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/melemapharma.de\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"http:\/\/melemapharma.de\/en\/wp-json\/wp\/v2\/pages\/108","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/melemapharma.de\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/melemapharma.de\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/melemapharma.de\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"http:\/\/melemapharma.de\/en\/wp-json\/wp\/v2\/comments?post=108"}],"version-history":[{"count":15,"href":"http:\/\/melemapharma.de\/en\/wp-json\/wp\/v2\/pages\/108\/revisions"}],"predecessor-version":[{"id":373,"href":"http:\/\/melemapharma.de\/en\/wp-json\/wp\/v2\/pages\/108\/revisions\/373"}],"wp:attachment":[{"href":"http:\/\/melemapharma.de\/en\/wp-json\/wp\/v2\/media?parent=108"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}